Roche Holding AG (RHHBY) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Roche Holding AG (RHHBY) Healthcare & Pipeline Overview

Roche Holding AG, a Swiss-based healthcare giant, develops and markets pharmaceutical and diagnostic products globally. With a strong presence in oncology, immunology, and infectious diseases, Roche leverages its diversified portfolio and robust R&D to maintain its competitive edge in the healthcare sector.

What Is the Investment Thesis for RHHBY?

With a P/E ratio of 22.60 and a profit margin of 20.9%, Roche demonstrates financial stability. A dividend yield of 3.04% offers an attractive return for investors. Key growth catalysts include the continued expansion of its oncology and immunology portfolios, as well as advancements in diagnostic technologies. Potential risks include regulatory challenges, competition from generic drugs, and the uncertainty of clinical trial outcomes. Investors should monitor pipeline developments and market dynamics to assess long-term value.

Based on FMP financials and quantitative analysis

RHHBY Key Highlights

Market capitalization of $339B reflects Roche's significant presence in the healthcare industry.

• P/E ratio of 22.60 indicates a reasonable valuation compared to its earnings.
• Profit margin of 20.9% demonstrates strong profitability and operational efficiency.
• Gross margin of 73.5% highlights the company's ability to maintain high pricing power and cost control.
• Dividend yield of 3.04% provides an attractive income stream for investors.

Who Are RHHBY's Competitors?

RHHBY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are RHHBY's Key Strengths?

Diversified product portfolio across pharmaceuticals and diagnostics.

• Strong research and development capabilities.
• Global presence and established market position.
• High gross margin and profitability.

What Are RHHBY's Weaknesses?

Exposure to generic competition for mature products.

• Dependence on successful clinical trial outcomes.
• Regulatory challenges and compliance risks.
• Potential for product recalls and liabilities.

What Could Drive RHHBY Stock Higher?

Continued expansion of the oncology portfolio with new drug approvals and indications.

• Advancements in diagnostic technologies and personalized healthcare solutions.
• Potential for strategic partnerships and acquisitions to expand product offerings.
• Clinical trial results for key pipeline candidates in neuroscience and immunology.
• Growth in emerging markets, particularly in China and India.

What Are the Key Risks for RHHBY?

Inconsistent delivery — missed Wall Street EPS estimates in 2 of the last 8 reported quarters.

• Exposure to generic competition for mature pharmaceutical products.
• Regulatory challenges and compliance risks in various markets.
• Uncertainty of clinical trial outcomes and drug development timelines.
• Pricing pressures and reimbursement challenges from healthcare providers.
• Intense competition from other pharmaceutical and diagnostic companies.

What Are the Growth Opportunities for RHHBY?

• Expansion in Oncology: Roche has a leading position in the oncology market, which is projected to reach $250 billion by 2028. By focusing on developing innovative cancer therapies and expanding its portfolio of targeted treatments, Roche can capitalize on the growing demand for personalized medicine. This includes advancements in immunotherapy and targeted therapies, potentially driving significant revenue growth over the next 3-5 years.
• Advancements in Diagnostics: The diagnostics market is expected to reach $115 billion by 2027, driven by the increasing need for early and accurate disease detection. Roche's diagnostics division can leverage its expertise in in-vitro diagnostics and molecular testing to develop new diagnostic solutions for various diseases, including infectious diseases and cancer. This expansion can enhance Roche's market share and contribute to long-term growth.
• Growth in Emerging Markets: Emerging markets, such as China and India, offer significant growth opportunities for Roche due to their large populations and increasing healthcare spending. By expanding its presence in these markets and tailoring its products and services to meet local needs, Roche can tap into new revenue streams and diversify its geographic footprint. This strategic expansion can contribute to sustainable growth over the next decade.
• Strategic Partnerships and Acquisitions: Roche can pursue strategic partnerships and acquisitions to expand its product portfolio and enhance its technological capabilities. By collaborating with other companies and acquiring innovative technologies, Roche can accelerate its R&D efforts and bring new products to market more quickly. These partnerships can provide access to novel therapies and diagnostic solutions, driving long-term growth and innovation.
• Personalized Healthcare Solutions: The trend towards personalized healthcare is creating new opportunities for Roche to develop targeted therapies and diagnostic solutions based on individual patient characteristics. By leveraging its expertise in genomics and data analytics, Roche can develop personalized treatment plans that improve patient outcomes and reduce healthcare costs. This focus on personalized healthcare can differentiate Roche from its competitors and drive long-term growth.

What Are RHHBY's Competitive Advantages?

• Strong intellectual property protection through patents.
• Extensive research and development capabilities.
• Established brand reputation and market presence.
• Diversified product portfolio across pharmaceuticals and diagnostics.
• Global distribution network and market access.

What Does RHHBY Do?

Founded in 1896 in Basel, Switzerland, Roche Holding AG has evolved into a leading global healthcare company. Initially focused on manufacturing chemicals and vitamins, Roche transitioned to pharmaceuticals in the early 20th century. Key milestones include the development of innovative medicines and diagnostic tools that have transformed healthcare. Today, Roche operates through two primary divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals division offers treatments for various diseases, including oncology, neuroscience, infectious diseases, immunology, cardiovascular and metabolism, ophthalmology, and respiratory conditions. The Diagnostics division provides in vitro tests and diagnostic systems used in hospitals, laboratories, and point-of-care settings. Roche's geographic reach spans across Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and other international markets. The company competes with other major pharmaceutical and diagnostic companies, emphasizing innovation and strategic partnerships to maintain its market position.

What Products and Services Does RHHBY Offer?

• Develops and markets pharmaceutical products for various therapeutic areas.
• Offers in-vitro diagnostic tests for disease diagnosis.
• Provides diagnostic instruments and reagents for laboratories.
• Focuses on oncology, neuroscience, infectious diseases, and immunology.
• Offers treatments for cardiovascular and metabolic disorders.
• Develops solutions for ophthalmology and respiratory conditions.
• Provides products for anemia, cancer, dermatology, and hemophilia.

How Does RHHBY Make Money?

• Develops and manufactures pharmaceutical products.
• Creates and distributes diagnostic tests and systems.
• Generates revenue through product sales and licensing agreements.
• Invests heavily in research and development to drive innovation.

What Industry Does RHHBY Operate In?

Roche Holding AG operates in the global healthcare industry, which is characterized by continuous innovation, stringent regulations, and intense competition. The pharmaceutical and diagnostics markets are driven by factors such as aging populations, increasing prevalence of chronic diseases, and technological advancements. The industry is highly competitive, with major players like Roche, AZNCF (AstraZeneca PLC), and CHGCF (Chugai Pharmaceutical Co., Ltd.) vying for market share. Roche's diversified portfolio and strong R&D capabilities position it well to capitalize on emerging trends and maintain its competitive advantage.

Who Are RHHBY's Key Customers?

• Hospitals and clinics
• Diagnostic laboratories
• Research institutions
• Pharmacies

Roche Holding AG Financial Trajectory

Roche Holding AG (RHHBY) reported $31.02B in revenue for Q2 FY2026, reflecting 2.3% growth compared to the prior quarter. The company recorded net income of $7.02B, with diluted EPS of $1.08. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this mega-cap Healthcare company. Across the four most recent quarters, RHHBY averaged $0.71 in diluted EPS.

Company Profile

Roche Holding AG operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Basel, CH. The company is led by CEO Thomas Schinecker. RHHBY has traded publicly since 2003.

How Roche Holding AG Is Valued

Roche Holding AG carries a market capitalization of $339B, placing it in the mega-cap category. Analyst price targets span from $63.00 to $63.00, with a consensus of $63.00. At the current price of $53.19, that implies approximately 18% upside potential. Relative to its peer group, RHHBY's quantitative score of 61/100 is roughly in line with the peer average of 69/100.

Return on equity for Roche Holding AG stands at 41.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 12.8%, showing how much profit it generates from its asset base. RHHBY trades at a trailing price-to-earnings ratio of 22.60, roughly in line with the Healthcare sector average of ~21.50x. Its free cash flow yield is 4.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.38 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.9%, the inverse of the P/E and a quick read on earnings relative to price.

Roche Holding AG's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 5.66 places it in the safe zone, indicating low near-term bankruptcy risk.

Roche Holding AG has missed Wall Street's EPS estimate in 2 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 2.2% above estimates on average.

RHHBY Financials

RHHBY Latest News

RHHBY Analyst Consensus

RHHBY MoonshotScore

Latest Roche Holding AG Analysis

Roche Holding AG Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources